Changes in Serum Electrolytes at Different Glucose Concentrations + Impact on a Non-invasive Glucose Monitoring Method
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In healthy subjects: Continuous monitoring of the glucose concentration in the skin by means of a non-invasive glucose sensor during a glucose clamp when systematically changing the blood glucose concentration (e.g. to hyperglycemia). Simultaneous frequent determinations of serum electrolytes.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetes Mellitus |
Device: Non-invasive CGMS Procedure: Hyperglycemic glucose clamp |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Pharmacokinetics/Dynamics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Single Center, Open Study to Evaluate Changes in Serum Electrolytes at Different Glucose Concentrations and Their Impact on a Non-invasive Glucose Monitoring Method |
- plasma ion concentrations (sodium, potassium, chloride, calcium, magnesium) and osmolarity [ Time Frame: blood samples every 10 min during baseline, plateau hyperglycemic and final euglycemic phase, every 5 min during increase and decrease of blood glucose ] [ Designated as safety issue: No ]
- blood glucose concentration [ Time Frame: continuously during glucose clamp ] [ Designated as safety issue: Yes ]
| Enrollment: | 20 |
| Study Start Date: | December 2001 |
| Study Completion Date: | August 2002 |
| Primary Completion Date: | May 2002 (Final data collection date for primary outcome measure) |
-
Device: Non-invasive CGMS
- Biostator
- Somatostatin
Non-invasive continuous glucose monitoring is a promising approach in diabetes therapy. It is known that changes in glucose concentration in the skin can be registered by means of optical, spectroscopic measures in subjects with diabetes. The precision of such measures, however, so far has been unsatisfactory.
This study evaluates the changes in skin glucose concentration by means of a non-invasive glucose sensor and compares these to blood glucose concentrations during a glucose clamp. It is also known that with hyperglycemic blood glucose concentrations there is a consecutive hyponatraemia. This study shall evaluate to which extent and how fast serum electrolyte parameters change when establishing a hyperglycaemic blood glucose level. This shall help estimate which impact these changes in electrolytes have on the non-invasive glucose sensor.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Written informed consent
- Age between 18 and 65 years
Exclusion Criteria:
- Uncontrolled hypertension (diastolic blood pressure > 100 mmHG and/or systolic blood pressure > 180 mmHg)
- Pregnancy or lactation period for female subjects
- Serious clinical signs of a liver disease, acute or chronic hepatitis, acute or chronic kidney disease, or ALAT > 2.5 times the upper level of normal values, or serum creatinine > 1.3 mg/dL (women)/1.5 mg/dL (men)
- Any serious acute illness (at the decision of the investigator), e.g. sepsis, gastric or duodenal ulcer, acute myocardial infarction, acute asthma attack
- Any other serious chronic illness (at the decision of the investigator), e.g. chronic obstructive pulmonary disease, any kind of cancer
Contacts and Locations| Germany | |
| Profil Institut für Stoffwechselforschung GmbH | |
| Neuss, Germany, 41460 | |
| Principal Investigator: | Christoph Kapitza, MD | Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany |
More Information
No publications provided
| Responsible Party: | Christoph Kapitza, MD, Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany |
| ClinicalTrials.gov Identifier: | NCT01058577 History of Changes |
| Other Study ID Numbers: | B1-2001-01 |
| Study First Received: | January 27, 2010 |
| Last Updated: | January 27, 2010 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Keywords provided by Profil Institut für Stoffwechselforschung GmbH:
|
diabetes |
Additional relevant MeSH terms:
|
Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Somatostatin |
Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013